Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate

Back to Search
Print
Bookmark Trial

NCT00628095

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Mesa, Arizona, 85202, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Arthritis, Rheumatoid
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Active rheumatoid arthritis

- Incomplete response to methotrexate

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Must not be on biologic therapies


- No recent infections

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Arthritis, RheumatoidStudy of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate
NCT00628095
  1. Mesa, Arizona
  2. Debary, Florida
  3. Lake Mary, Florida
  4. Tampa, Florida
  5. Avon, Indiana
  6. New Orleans, Louisiana
  7. Frederick, Maryland
  8. Columbia, Missouri
  9. Columbia, Missouri
  10. Reno, Nevada
  11. Cincinnati, Ohio
  12. Spokane, Washington
  13. Providencia, Santiago, RM
  14. Ceska Lipa,
  15. Praha 2,
  16. Praha 4,
  17. Incheon,
  18. Pusan,
  19. Mexico, D.f.
  20. Krakow,
  21. Poznan,
  22. Poznan,
  23. Santiago de Compostela, A Coruña
  24. A Coruña,
  25. Madrid,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Arthritis, RheumatoidEtanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan)
NCT01230177
  1. Sendai, Miyagi
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Arthritis, RheumatoidStudy To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis
NCT00440492
  1. Los Angeles, California
  2. Palo Alto, California
  3. Lake Success, New York
  4. Rochester, New York
  5. Charlotte, North Carolina
  6. Columbus, Ohio
  7. Vancouver, British Columbia
  8. Mississauga, Ontario
  9. Montreal, Quebec
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Arthritis, RheumatoidDose-Escalating Multiple Dose Study of PD-0360324 in Combination With Methotrexate in Patients With Rheumatoid Arthritis
NCT00550355
  1. Peoria, Arizona
  2. Daytona Beach, Florida
  3. Port Orange, Florida
  4. Overland Park, Kansas
  5. Overland Park, Kansas
  6. Frederick, Maryland
  7. Lansing, Michigan
  8. Duncansville, Pennsylvania
  9. Dallas, Texas
  10. Buenos Aires,
  11. Pleven,
  12. Sofia,
  13. Sofia,
  14. Brno,
  15. Praha 4,
  16. Mexico, D.f.
  17. Mexico, DF
  18. Bialystok,
  19. Bialystok,
  20. Krakow,
  21. Krakow,
  22. Warszawa,
  23. Wroclaw,
  24. Piestany,
  25. Santiago de Compostela, A Coruña
ALL GENDERS
21 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate
Official Title  ICMJE A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of CE-224,535, An Antagonist Of The P2x7 Receptor, In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis In Subjects Who Are Inadequately Controlled On Methotrexate
Brief Summary CE-224,535 is known to block a chemical that acts as a gateway to some of your immune cells. Blocking this gateway prevents the cells from pushing out 2 chemicals called IL-1 and IL-18 that are known to cause some of the inflammation seen in rheumatoid arthritis. It is hoped that taking this drug will reduce the symptoms of rheumatoid arthritis
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Arthritis, Rheumatoid
Intervention  ICMJE
  • Drug: CE-224,535
    500 mg po BID
  • Drug: Placebo
    no active ingredient
Study Arms  ICMJE
  • Experimental: Active
    Intervention: Drug: CE-224,535
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Publications * Stock TC, Bloom BJ, Wei N, Ishaq S, Park W, Wang X, Gupta P, Mebus CA. Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012 Apr;39(4):720-7. doi: 10.3899/jrheum.110874. Epub 2012 Mar 1.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 13, 2009)		100
Original Estimated Enrollment  ICMJE
 (submitted: February 25, 2008)		86
Actual Study Completion Date  ICMJE February 2009
Actual Primary Completion Date February 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Active rheumatoid arthritis
  • Incomplete response to methotrexate

Exclusion Criteria:

  • Must not be on biologic therapies
  • No recent infections
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Chile,   Czech Republic,   Korea, Republic of,   Mexico,   Poland,   Spain,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00628095
Other Study ID Numbers  ICMJE A6341009
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP